Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 24/5/2020
SIETES contiene 93008 citas

 1 a 9 de 9 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Sherman RB, Woodcock J, Norden J, Grandinetti C, Temple RJ. New FDA regulation to improve safety reporting in clinical trials. N Engl J Med 2011;365:3-5. [Ref.ID 90902]
2.Tiene citas relacionadas
Temple RJ, Himmel MH. Postmarketing surveillance and black box warnings. In reply. JAMA 2002;288:958-9. [Ref.ID 63109]
3.Tiene citas relacionadas
Temple RJ, Himmel MH. Safety of newly approved drugs. Implications for prescribing. JAMA 2002;287:2273-5. [Ref.ID 61652]
Temple RJ. When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?. Control Clin Trial 1997;18:613-20. [Ref.ID 36201]
5.Tiene citas relacionadas
Kessler DA, Rose J L, Temple RJ, Schapiro R, Griffin JP. Drug promotion. N Engl J Med 1995;332:1033. [Ref.ID 33832]
Temple RJ. The clinical pahrmacologist in drug regulation: the US perspective. Br J Clin Pharmacol 1996;42:73-9. [Ref.ID 28196]
Choudary J, Contrera JF, DeFelice A, DeGeorge JJ, Farrelly JG, Fitzgerald G, Goheer MA, Jacobs A, Jordan A, Meyers L, Ostergerg R, Resnick Ch, Sun J, Temple RJ. Response to Monro and Mehta proposal for use of single-dose toxicology studies to support single-dose studies of new drugs in humans. Clin Pharmacol Ther 1996;59:265-7. [Ref.ID 28003]
8. Cita con resumen
Kessler DA, Rose J L, Temple RJ, Shapiro R, Griffin JP. Therapeutic-class wars - drug promotion in a competitive marketplace. N Engl J Med 1994;331:1350-3. [Ref.ID 23109]
Coppinger PL, Peck C C, Temple RJ. Understanding comparisons of drug introductions between the United States and the United Kingdom. Clin Pharmacol Ther 1989;46:139-45. [Ref.ID 12591]
Seleccionar todas
 1 a 9 de 9